DUPIXENT Helps Break THE CYCLE OF RECURRENCE^1-3

92^%

reduction

In the need for sinus surgery
and/or systemic STEROIDS THROUGH WEEK 52

with DUPIXENT compared to placebo (HR: 0.079
[95% CI: 0.001, 0.627]) (secondary endpoint)¹

• No patients (0%) receiving DUPIXENT (n=33) needed sinus surgery vs 2 patients (6.9%) receiving placebo (n=29)¹
• 1 patient (3%) receiving DUPIXENT (n=33) needed systemic steroids vs 9 patients (31%) receiving placebo (n=29)¹

Primary endpoint:

9.17 reduction in sinus opacification as measured by LMK-CT score at Week 52 from a baseline score of 17.50
with DUPIXENT (n=33) vs 1.81 reduction from a baseline score of 18.45 with placebo (n=29); LSM difference: -7.36 (95% CI: -9.38, -5.35) (P<0.0001).^1,2

HR, hazard ratio; LMK-CT, Lund-Mackay computed tomography; LSM, least squares mean.